NEW YORK, May 17, 2025 —
Rosen Law Firm, a global law firm protecting investor rights, is notifying those who purchased stock in Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023, and November 4, 2024, inclusive, about the May 20, 2025, deadline to seek the role of lead plaintiff.
If you acquired Sana securities during the specified period, you could be eligible for financial compensation without having to pay any upfront legal fees due to a contingency-based payment structure.
To participate in the Sana class action, visit or contact Phillip Kim, Esq., toll-free at 866-767-3653 or via email at for details regarding the class action. A lawsuit has already been initiated. Those interested in serving as the lead plaintiff must file a motion with the court by May 20, 2025. The lead plaintiff will represent the collective interests of other class members in directing the legal proceedings.
Investors are advised to choose qualified legal representation with a proven history of success in leadership positions. It is important to note that many firms issuing notices may lack the necessary experience, resources, or industry recognition. Some of these firms may only act as intermediaries, referring clients or collaborating with law firms that handle the actual litigation. The Rosen Law Firm advocates for investors worldwide, focusing on securities class actions and shareholder derivative litigation. The firm previously secured the largest securities class action settlement against a Chinese company at the time. Rosen Law Firm was recognized as the top firm for the number of securities class action settlements by ISS Securities Class Action Services in 2017. Since 2013, the firm has consistently ranked in the top 4 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm obtained over $438 million for investors. In 2020, founding partner Laurence Rosen was distinguished as a Titan of the Plaintiffs’ Bar by Law360. Several of the firm’s attorneys have received accolades from Lawdragon and Super Lawyers.
The lawsuit alleges that, throughout the Class Period, the defendants made misleading statements and/or failed to disclose that: (1) Sana faced a significant risk of lacking sufficient capital to sustain its present operations and advance its pipeline; (2) SC291 in oncology, SC379, and SG299 were less promising than the defendants represented; (3) to conserve funds and prioritize more viable candidates, Sana was likely to cut funding for or discontinue SC291 in oncology, SC379, and SG299, and implement significant layoffs; (4) consequently, the defendants overstated Sana’s ability to fund its operations and develop existing product candidates; and (5) as a result, the defendants’ public statements were materially false and misleading. The lawsuit asserts that investors suffered losses when the truth became known.
To participate in the Sana class action, go to or contact Phillip Kim, Esq. toll-free at 866-767-3653 or email for information on the class action.
No Class Has Been Certified. You are not represented by legal counsel unless you formally retain one, and this will only occur if a class is certified. You have the option to choose your own legal representation. Alternatively, you can remain an absent class member without taking any action at this time. An investor’s potential to receive any compensation is not contingent upon serving as lead plaintiff.
Follow updates on LinkedIn: , Twitter: or Facebook: .
Attorney Advertising. Past outcomes do not guarantee future success.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
SOURCE THE ROSEN LAW FIRM, P. A.
“`